In the current study, we focused on the interactions between wild-type NR2E3, NR2E3 mutations, NR2E3’s agonist 11a, and p53 to enhance our understanding of NR2E3 as a novel molecular target in cancer. This evidence concerns the gene TP53 and cancer.